About Kura Oncology
Kura Oncology (NASDAQ:KURA) is dedicated to the research and development of new therapies aimed at treating various cancers. Specializing in precision medicine, the company seeks to identify and advance oncologic drugs that have the potential to improve outcomes for patients facing this challenging disease. Their portfolio includes several projects in different stages of clinical development, focusing primarily on targeted treatments that may offer significant benefits over existing therapies. Kura Oncology's objective is to continue pushing the boundaries of cancer treatment, leveraging cutting-edge science and technology to develop drugs that can provide real hope to patients and their families in need. The company operates with a strong commitment to innovation, patient care, and the advancement of oncology treatment options.
Snapshot
Operations
Products and/or services of Kura Oncology
- Tipifarnib is a farnesyl transferase inhibitor designed for the treatment of HRAS mutant head and neck squamous cell carcinomas.
- KO-2806 is a next-generation farnesyl transferase inhibitor aimed at improving safety and efficacy over prior inhibitors.
- Menin-MLL inhibitors target acute leukemias characterized by rearrangements of the MLL (Mixed Lineage Leukemia) gene.
- KO-539 is a potent, small molecule inhibitor of the menin-KMT2A (MLL) interaction, focused on acute myeloid leukemia.
- Preclinical programs are focused on developing novel therapeutics for other cancers with specific genetic mutations or alterations.
- Collaboration and licensing agreements with other pharmaceutical companies to enhance research, development, and commercialization of their pipeline.
Kura Oncology executive team
- Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO & President
- Ms. Kathleen FordChief Operating Officer
- Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporate Secretary
- Mr. Thomas DoyleSenior Vice President of Finance & Accounting
- Dr. Francis J. Burrows Ph.D.Chief Scientific Officer
- Mr. Greg MannSenior Vice President of Investor Relations & Corporate Affairs
- Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply Chain
- Ms. Maureen Clancy M.B.A.VP and Global Head of Program Leadership & Project Management
- Dr. Mollie Leoni M.D.Chief Medical Officer
- Mr. Brian T. Powl M.B.A., M.S.Chief Commercial Officer